Skip to main content
Premium Trial:

Request an Annual Quote

Japanese Patent Office Grants Claims in Alnylam's Tuschl-II Application

Premium

Alnylam Pharmaceuticals said this week that the Japanese Patent Office has granted claims in a second patent application in the so-called Tuschl II patent series.

The application, No. 2006-317758, is entitled, "RNA Interference Mediating Small RNA Molecules," according to the company.

The patent "includes 38 claims broadly covering compositions, methods, uses, and systems for double-stranded RNAs having key structural elements that are widely recognized as important for the therapeutic activity of siRNAs," Alnylam said. The Japanese Patent Office granted a related set of claims in May last year, it noted.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.